Successful Drug Discovery最新文献

Index 指数

Successful Drug Discovery Pub Date : 2021-02-26 DOI: 10.1002/9783527826872.index

引用次数: 0

Discovery of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease 替替肽治疗慢性肾病继发性甲状旁腺功能亢进症的发现

Successful Drug Discovery Pub Date : 2019-10-07 DOI: 10.1002/9783527814695.ch5

A. Baruch, D. Maclean

引用次数: 1

Ocrelizumab: A New Generation of anti‐CD20 mAbfor Treatment of Multiple Sclerosis Ocrelizumab:新一代抗CD20单抗治疗多发性硬化症

Successful Drug Discovery Pub Date : 2019-10-07 DOI: 10.1002/9783527814695.ch7

A. Chan, P. Brunetta, P. Chin

引用次数: 0

Physicochemical Parameters of Recently Approved Oral Drugs 最近批准的口服药物的理化参数

Successful Drug Discovery Pub Date : 2019-07-19 DOI: 10.1002/9783527814695.ch2

A. Ritzén, L. David

引用次数: 3

Development of Lenvatinib Mesylate, an Angiogenesis Inhibitor TargetingVEGFandFGFReceptors 靶向vegf和fgf受体血管生成抑制剂甲磺酸Lenvatinib的研究进展

Successful Drug Discovery Pub Date : 2019-07-19 DOI: 10.1002/9783527814695.ch6

A. Tsuruoka, Y. Funahashi, J. Matsui, T. Matsushima

引用次数: 2

Discovery and Development of Venetoclax, a Selective Antagonist ofBCL‐2 bcl - 2选择性拮抗剂Venetoclax的发现与开发

Successful Drug Discovery Pub Date : 2019-07-19 DOI: 10.1002/9783527814695.ch9

W. Fairbrother, J. Leverson, D. Sampath, A. Souers

引用次数: 2

Antibody–Drug Conjugates: Empowering Antibodies for the Fight Against Cancer 抗体-药物结合物:增强抗体对抗癌症

Successful Drug Discovery Pub Date : 2019-07-19 DOI: 10.1002/9783527814695.ch3

Caroline Denevault-Sabourin, F. Bryden, M. Viaud-Massuard, Nicolas Joubert

引用次数: 4

Trends in Peptide Therapeutics 肽疗法的发展趋势

Successful Drug Discovery Pub Date : 2019-07-19 DOI: 10.1002/9783527814695.ch1

F. Brunel, Fa Liu, J. Mayer

{"title":"Trends in Peptide Therapeutics","authors":"F. Brunel, Fa Liu, J. Mayer","doi":"10.1002/9783527814695.ch1","DOIUrl":"https://doi.org/10.1002/9783527814695.ch1","url":null,"abstract":"The growing importance of peptide drugs within the pharmacopoeia has become evident over the past several decades. Among the factors that have contributed to this trend is the recognition that peptide ligands regulate a multitude of physiological pathways and are often suitable for therapeutic applications, in either their native or modified form. In addition, certain attributes that are unique to peptides, such as their high selectivity, potency, and lack of toxicity, have ultimately become appreciated. The alternative means of drugging peptide receptors through target‐directed screening or rational design of orally available small molecules have, with few exceptions, proved unproductive. Mimicking the activity of a peptide agonist is highly challenging, particularly in the case of Class II G‐protein‐coupled receptor (GPCR) targets. Successful examples have typically involved receptor antagonists such as neurokinin, angiotensin, endothelin, and orexin. These lessons have increasingly led drug discovery scientists to consider peptides as legitimate drug candidates, rather than leads or proof‐of‐concept models for small‐molecule programs. Peptide medicinal chemists have also had to confront and overcome shortcomings such as rapid metabolism, clearance, production costs, and limited alternative delivery options. In the present chapter, we highlight the role of peptides in therapeutic areas such as metabolic disease, where peptides have been well established, as well as in areas where their impact has been minor, but now rapidly expanding. We also emphasize examples where time‐extension strategies and alternative delivery routes have helped establish and strengthen the position of peptide drugs in competitive markets. Finally, we explore two novel trends in peptide drug discovery, macrocyclic and cell‐penetrating peptides, both of which may expand future opportunities for peptide therapeutics. Trends in Peptide Therapeutics Florence M. Brunel, Fa Liu, and John P. Mayer","PeriodicalId":362351,"journal":{"name":"Successful Drug Discovery","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124409011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Dopamine D 2 Partial Agonists – Discovery, Evolution, and Therapeutic Potential 多巴胺d2部分激动剂-发现，进化和治疗潜力

Successful Drug Discovery Pub Date : 2019-07-19 DOI: 10.1002/9783527814695.ch4

M. Jacobson, W. Childers, M. Abou-Gharbia

引用次数: 0

The Story of Rucaparib (Rubraca) 鲁卡帕尼的故事(鲁布拉卡)

Successful Drug Discovery Pub Date : 2019-07-19 DOI: 10.1002/9783527814695.ch8

B. Golding

引用次数: 2